<DOC>
	<DOCNO>NCT01637532</DOCNO>
	<brief_summary>The purpose interventional study determine feasibility combine standard chemotherapy ( Carbo/Caelyx doxorubicin ) recurrent ovarian cancer immunotherapy ( Tocilizumab Peg-Intron ) . This study combine standard chemotherapy Carboplatin-Caelyx doxorubicin monoclonal antibody IL-6R ( tocilizumab ) . High IL-6 level correlate poor prognosis chemoresistance ovarian cancer patient . In case chemoresistant ovarian cancer , therefore , modulation IL-6 pathway , block IL-6 receptor , may represent promise strategy abolish drug resistance amplify host immunity patient recurrent ovarian cancer . Blockade IL-6/IL-6R pathway may enhance immunogenic cell death restore local normal DC maturation . In addition , use interferon-alpha ( Peg-Intron ) allow full maturation DC , thereby enhance anti-tumor response .</brief_summary>
	<brief_title>Feasibility Combination Chemotherapy ( Carbo/Caelyx Carbo/Doxorubicin ) With Tocilizumab ( mAb IL-6R ) Peg-Intron Patients With Recurrent Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Histologically proven epithelial ovarian cancer Progression disease relapse previous therapy platinum Measurable disease ( RECIST 1.1 ) elevate CA125 &gt; 2 time upper normal limit ( UNL ) within 3 month confirm Age ≥18 year WHO performance status 02 Adequate bone marrow function : WBC ≥3.0 x 109/l , neutrophil ≥1.5 x 109/l , platelet ≥100 x 109/l Adequate liver function : bilirubin ≤1.5 x UNL range , ALAT and/or ASAT 2.5 x UNL ( &lt; 5x UNL case liver metastasis ) , Alkaline Phosphatase ≤5 x UNL Adequate renal function : calculated creatinine clearance 50 mL/min Survival expectation &gt; 3 month Patients must accessible treatment followup Written inform consent accord local Ethics Committee requirement Chemotherapy within past 3 month Previous malignancy within 5 year , exception history previous basal cell carcinoma skin preinvasive carcinoma cervix Serious diseases recent myocardial infarction , clinical sign cardiac failure clinically significant arrhythmia Known hypersensitivity reaction component treatment Pregnancy lactate Medical psychological condition opinion investigator would permit patient complete study sign meaningful inform consent Infection tuberculosis hepatitis B C</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>